Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...
US biotech Regeneron is buying compatriot clinical-stage biopharma Checkmate Pharmaceuticals for a total equity value of about $250 million. The acquisition, expected to...
US biotech Regeneron is collaborating with AstraZeneca to research, develop and commercialize small molecule medicines targeting GPR75 for treating obesity.
02.05.2019
- French biotech Calixar has signed an exclusive licensing agreement with Regeneron Pharmaceuticals, granting the US company exclusive rights to its technology and expertise to...
10.01.2019
- France’s Sanofi is paying $462 million to exit the immuno-oncology pact it established with US biotech Regeneron in 2015 half a year earlier than planned. With the severance...
09.08.2018
- US biotech companies Regeneron and bluebird bio are collaborating and applying their respective technology platforms to discover, develop and commercialize novel immune cell...
29.03.2017
- UK drugmaker GlaxoSmithKline (GSK) and US biotech Regeneron Pharmaceuticals are investing in a gene sequencing project that uses anonymous patient data held by the UK Biobank. The...
11.01.2017
- French drugmaker Sanofi and US marketing partner Regeneron have announced they will appeal a ruling by a US federal district court judge that would prevent them from selling their...
